Tolimidone

N/A

Report date: 2024/06/27 16:46:58
NME

Base Information

Drug NameTolimidone
Drug Alias Name托利咪酮tolimidonetolimidonatolimidonumCP-26154 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase Lyn stimulants
TargetsTyrosine-protein kinase Lyn
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Metabolic Dysfunction-Associated Steatotic Liver Disease +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMelior DiscoveryBukwang Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBiodexa Pharmaceuticals PLCUniversity Of AlbertaPfizer Inc +[5] 
Inactive CompaniesBukwang Pharmaceutical Co Ltd
Active IndicationsDiabetes Mellitus, Type 1Metabolic Dysfunction-Associated Steatotic Liver DiseasePneumonia
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG